Business
ADMA Biologics Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
FY 2025 Total Revenue of $510 Million, Representing 20% Year-Over-Year Growth FY 2025 ASCENIV Revenue Grew to $363 Million, Representing 51% Year-Over-Year Growth FY 2025 Adjusted Net Income(1) of $161 Million, Representing 35% Year-Over-Year Growth FY 2025 Adjusted EBITDA(2) of $231 Million, Representing 40% Year-Over-Year Growth Incoming CFO Appointment Expected to Further Enhance Financial Strategy, Working Capital Execution and Capital Allocation Discipline Advancing SG-001 Pipeline Program
About this update from Adma Biologics Inc
[{"type":"image","alt":"ADMA Biologics, Inc.","displaySize":"","headline":null,"caption":"ADMA Biologics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":104,"url":"https://media.zenfs.com/en/globenewswire.com/d281b7fb332fa78959cbb0a9b0e9f249"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CFcL5DZ8C0U_qnTUgYd8kQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0NjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/d281b7fb332fa78959cbb0a9b0e9f249","width":300,"height":104}},"lazy":false},{"type":"text","content":"FY 2025 Total Revenue of $510 Million, Representing 20% Year-Over-Year Growth","length":77,"tagName":"p"},{"type":"text","content":"FY 2025 ASCENIV Revenue Grew to $363 Million, Representing 51% Year-Over-Year Growth","length":84,"tagName":"p"},{"type":"text","content":"FY 2025 Adjusted Net Income(1) of $161 Million, Representing 35% Year-Over-Year Growth","length":86,"tagName":"p"},{"type":"text","content":"FY 2025 Adjusted EBITDA(2) of $231 Million, Representing 40% Year-Over-Year Growth","length":82,"tagName":"p"},{"type":"text","content":"Incoming CFO Appointment Expected to Further Enhance Financial Strategy, Working Capital Execution and Capital Allocation Discipline","length":132,"tagName":"p"},{"type":"text","content":"Advancing SG-001 Pipeline Program with Anticipated FDA Pre-IND Meeting in 2026; Potential Accelerated Path to Registrational Trial","length":130,"tagName":"p"},{"type":"text","content":"Ongoing Share Repurchases and Capital Structure to Increase Stockholder Value","length":77,"tagName":"p"},{"type":"text","content":"Reiterating Previously Provided 2026-2029 Financial Guidance ","length":60,"tagName":"p"},{"type":"text","content":"RAMSEY, N.J. and BOCA RATON, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced its fourth quarter and full year 2025 financial results and provided a business update.","length":371,"tagName":"p"},{"type":"text","content":"“2025 marked a year of disciplined execution, record performance and meaningful strategic progress for ADMA, and we are entering 2026 with significant momentum,” said Adam Grossman, President and Chief Executive Officer of ADMA. “Record ASC...